Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept.

Diabetes Obes Metab · 2026 · PMC12992164 · PMID 41559929

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

3.4.5 Overall appetite On Day 81, there was a nonsignificant trend for mean overall fasting appetite scores to increase compared to Day −1 (corresponding to decreased overall appetite) in the eloralintide‐treated groups, while these scores decreased in the placebo‐treated participants (Table S7 ).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.